After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...
Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance ...
Hosted on MSN1mon
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...
Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...
Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...
Cipla share price today: The pharma major reported a 49% increase in net profit, reaching Rs 1,571 crore (Image: Reuters) Motilal Oswal has maintained a Neutral rating on Cipla, with a target ...
Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...
Cipla, one of the leading pharmaceutical companies in India, released its December quarter numbers (Q3FY25) on Tuesday, January 28, reporting a 48% year-on-year (YoY) jump in its consolidated net ...
Learn about Cipla Ltd in Goa.Find comprehensive contact details, including phone numbers and email addresses, and get directions to the location. If you own or are associated with Cipla Ltd and ...
Laurus Labs slumped 11.6%, Aurobindo declined 2%, Cipla fell 1.1% and Strides dropped 5%. Other pharma shares also declined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback